Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the most effective dose of a new enzyme therapy on
oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic
insufficiency.
Phase:
Phase 2
Details
Lead Sponsor:
Anthera Pharmaceuticals
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics